Furthermore, the authors utilized the small molecule inhibitor, indisulam (E7070), which selectively degrades RBM39, on human MLL-AF9 AML cell lines and observed dose-dependent decreases in the expression of RBM39 and HOXA9 targets as well as increased apoptosis. This evidence concerns the gene RBM39 and acute myeloid leukemia.